Business
Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
LYON, France, May 26, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that the abstract featuring previously announced preclinical data demonstrating positive results for PXL065, the deuterium-stabilized R-enantiomer of pioglitazone
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/bcd9c08a8d3843883fdec789f47c0c9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mTF3JjFwkkgXzUOI0M_bHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bcd9c08a8d3843883fdec789f47c0c9b","width":480,"height":256}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"PXL065 demonstrated significant benefits in a HCM mouse model preventing pathological myocardial remodeling, including hypertrophy and fibrosis in the heart","length":156,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presentation of detailed results from preclinical study on Sept 1st, 2025, 11:15 am CEST, at the European Society of Cardiology 2025","length":132,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Findings support the clinical development of PXL065 as a potential disease- modifying treatment for symptomatic and asymptomatic HCM patients","length":141,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":429,"olType":false},{"type":"text","content":"LYON, France, May 26, 2025--(BUSINESS WIRE)--Regulatory News:","length":61,"tagName":"p"},{"type":"text","content":"POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that the abstract featuring previously announced preclinical data demonstrating positive results for PXL065, the deuterium-stabilized R-enantiomer of pioglitazone, in hypertrophic cardiomyopathy1, has been accepted for presentation at the 2025 edition of the European Society of Cardiology (ESC) Congress (link), to be held jointly with World Congress of Cardiology, on September 1st, 2025 at 11:15 am CEST, in Madrid, Spain.","length":718,"tagName":"p"},{"type":"text","content":"Prof. Dr. Cordula Wolf, Director of the Center for Rare Congenital Heart Diseases at the TUM University Hospital German Heart Center, stated: "The compelling results obtained in this study illustrate the potential ...